Current pathological and molecular aspects of bladder cancer

Journal article

Publication Details

Author(s): Hartmann A, Schwamborn K, Kristiansen G, Knuechel-Clarke R
Journal: Onkologe
Publication year: 2018
Volume: 24
Journal issue: 1
Pages range: 14-22
ISSN: 0947-8965


Background and results. Key data of the World Health Organization (WHO) classification from 2016 for the entity of urinary bladder cancer are summarized in the first part of this article. Unequivocal diagnostic terms in addition to clinical data of the findings in the bladder are an important basis in order to expedite a better molecular genetic understanding of tumors and their formation. At the same time increasing molecular data show the possibilities for definitive statements on subtypes and variants of urothelial cancer up to initial data on therapy response, so that overall substantial progress has been achieved for bladder cancer. Last but not least, greater certainty on the use of immunohistochemical investigations can be deduced from the molecular genetic data. Immunohistochemistry plays an important role in the definition of the urothelial entity (e. g. for metastases) and in the definitive assignment of malignancies and the differentiation from reactive changes, e.g. with the staining of targeted molecules within the immune checkpoint control, immunohistochemistry also provides a predictive component.
Conclusion. Novel genetic and proteomic methods are increasingly being used for the diagnostics of urine and tissue of the urinary tract.

FAU Authors / FAU Editors

Hartmann, Arndt Prof. Dr. med.
Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

External institutions with authors

Technische Universität München (TUM)
Universitätsklinikum Aachen
Universitätsklinikum Bonn

How to cite

Hartmann, A., Schwamborn, K., Kristiansen, G., & Knuechel-Clarke, R. (2018). Current pathological and molecular aspects of bladder cancer. Onkologe, 24(1), 14-22.

Hartmann, Arndt, et al. "Current pathological and molecular aspects of bladder cancer." Onkologe 24.1 (2018): 14-22.


Last updated on 2018-12-11 at 03:37